<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940160</url>
  </required_header>
  <id_info>
    <org_study_id>CQAX576A2107</org_study_id>
    <nct_id>NCT00940160</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Study To Compare The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of Intravenous Administration Of QAX576 In Controlled Or Partially Controlled Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety and tolerability of multiple doses of QAX576&#xD;
      in controlled or partially controlled asthma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Assessing and comparing the safety and tolerability of multiple doses of QAX576 in controlled and partially controlled asthma patients.</measure>
    <time_frame>120 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing the pharmacokinetics of multiple doses of QAX576 in asthmatics</measure>
    <time_frame>120 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the effect of QAX576 on asthma control using assessments such as exhaled NO, FEV1 variability data captures by PIKO-1 home monitoring device and the extent of inhaled salbutamol use as rescue medication.</measure>
    <time_frame>120 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>QAX576 1 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAX576 3 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAX576 10 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576</intervention_name>
    <arm_group_label>QAX576 1 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576</intervention_name>
    <arm_group_label>QAX576 3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576</intervention_name>
    <arm_group_label>QAX576 10 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-smoking male and female subjects age 18 to 65 years, inclusive; with controlled or&#xD;
             partially controlled asthma who are otherwise healthy as determined by past medical&#xD;
             history, physical examination, vital signs, electrocardiogram, and laboratory tests at&#xD;
             screening. Female subjects are allowed to participate in this study if they are&#xD;
             postmenopausal or surgically sterilized.&#xD;
&#xD;
          -  Controlled or partially controlled asthma as defined in GINA 2007.&#xD;
&#xD;
          -  At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and&#xD;
             pulse rate) will be assessed after the subject has rested for at least three (3)&#xD;
             minutes.&#xD;
&#xD;
          -  Female subjects must be post-menopausal as confirmed by FSH â‰¥ 40, or have been&#xD;
             surgically sterilized at least 6 months prior to screening.&#xD;
&#xD;
          -  Subjects must have a body mass index (BMI) within the range of 18 to 30 kg/m2.&#xD;
&#xD;
          -  Male subjects must be using two methods of contraception, i.e., spermicidal gel plus&#xD;
             condom, for the entire duration of the study, up to Study Completion visit, and&#xD;
             refrain from fathering a child in the six (6) months after study completion&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Smokers (use of tobacco products in the previous 3 months).&#xD;
&#xD;
          -  Use of any prescription drugs other than stable (4 weeks) use of hormone replacement&#xD;
             or thyroid replacement within four (4) weeks prior to dosing (other than medication&#xD;
             required for treatment of asthma).&#xD;
&#xD;
          -  Use of any over the counter (OTC) medication within forty eight (48) hours prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Use of oral steroids within 12 weeks prior to dosing.&#xD;
&#xD;
          -  Patients who have received an investigational drug in any clinical investigation&#xD;
             within 4 weeks prior to dosing or longer if required by local regulations, and for any&#xD;
             other limitation of participation based on local regulations.&#xD;
&#xD;
          -  Any immunotherapy with systemic biologics as a treatment therapy or during a clinical&#xD;
             study with in the last 6 months.&#xD;
&#xD;
          -  Any immunotherapy with subcutaneous injections for allergy (allergy shots), within 3&#xD;
             months.&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or&#xD;
             longer if required by local regulation.&#xD;
&#xD;
          -  Patients suffering from hay fever at screening or likely to require treatment during&#xD;
             the study.&#xD;
&#xD;
          -  History of chronic respiratory disease other than asthma or chronic allergic rhinitis.&#xD;
&#xD;
          -  Hospitalization for asthma in the last year.&#xD;
&#xD;
          -  History of intubation/assisted ventilation for asthma in the last 5 years.&#xD;
&#xD;
          -  History of autonomic dysfunction (e.g. history of fainting, orthostatic hypotension).&#xD;
&#xD;
          -  History or presence of any surgical or medical condition or clinically significant&#xD;
             abnormal laboratory findings, which, in the opinion of the investigator, may&#xD;
             jeopardize the subject in case of participation in the study.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 12 months prior to dosing or evidence of&#xD;
             such abuse as indicated by the laboratory assays conducted during the screening or&#xD;
             baseline evaluations.&#xD;
&#xD;
          -  History of clinical schistosomiasis or travel within the preceding 6 months to an area&#xD;
             with endemic schistosomiasis, including but not limited to Southeast Asia and&#xD;
             Northwest Africa.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5704</url>
    <description>Results for CQAX576A2107 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

